A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer ; volume:8 ; number:1 ; day:23 ; month:2 ; year:2024 ; pages:1-13 ; date:12.2024
npj precision oncology ; 8, Heft 1 (23.2.2024), 1-13, 12.2024
- Creator
-
Suzuki, Mai
Uchibori, Ken
Oh-hara, Tomoko
Nomura, Yumi
Suzuki, Ryusei
Takemoto, Ai
Araki, Mitsugu
Matsumoto, Shigeyuki
Sagae, Yukari
Kukimoto-Niino, Mutsuko
Kawase, Yusuke
Shirouzu, Mikako
Okuno, Yasushi
Nishio, Makoto
Fujita, Naoya
Katayama, Ryohei
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41698-024-00542-9
- URN
-
urn:nbn:de:101:1-2404301313210.691906830847
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Suzuki, Mai
- Uchibori, Ken
- Oh-hara, Tomoko
- Nomura, Yumi
- Suzuki, Ryusei
- Takemoto, Ai
- Araki, Mitsugu
- Matsumoto, Shigeyuki
- Sagae, Yukari
- Kukimoto-Niino, Mutsuko
- Kawase, Yusuke
- Shirouzu, Mikako
- Okuno, Yasushi
- Nishio, Makoto
- Fujita, Naoya
- Katayama, Ryohei
- SpringerLink (Online service)
Other Objects (12)
Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
Lack of epidermal growth factor receptor (EGFR)-activating mutations in triple-negative breast cancer in China
Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
EGFR exon 20 insertion mutations in NSCLC
AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
Profiling of driver mutations in lung adenocarcinoma patients identifies rare compound EGFR mutations sensitive to second-generation EGFR-TKIs
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
Poetry overcomes boundaries
Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy
Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
Lack of epidermal growth factor receptor (EGFR)-activating mutations in triple-negative breast cancer in China
Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
EGFR exon 20 insertion mutations in NSCLC
AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
Profiling of driver mutations in lung adenocarcinoma patients identifies rare compound EGFR mutations sensitive to second-generation EGFR-TKIs
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
Poetry overcomes boundaries
Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy
Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
Lack of epidermal growth factor receptor (EGFR)-activating mutations in triple-negative breast cancer in China
Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
EGFR exon 20 insertion mutations in NSCLC
AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
Profiling of driver mutations in lung adenocarcinoma patients identifies rare compound EGFR mutations sensitive to second-generation EGFR-TKIs
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
Poetry overcomes boundaries